Condition: Long Covid · Sponsor: Icahn School of Medicine at Mount Sinai
The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid. Participants will be randomly allocated to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine, TDF/FTC, Group 1) or Selzentry (Group 2), or a placebo (pill) (Group 3), taken daily for 90 days.
This description comes directly from the study's public registry record.
David Putrino, PhD, PT · 212-241-8454 · CoreResearch@mountsinai.org
Mackenzie Doerstling, MPH · 212-241-8454 · CoreResearch@mountsinai.org
Always discuss trial participation with your own doctor first.
| The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06511063